Features

What is the outlook for biomanufacturing (drug substance)? How is industry capacity trending, and what is the outlook for outsourcing? A recent study by BioPlan Associates reveals key insights.

The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a legal complaint that challenges the US government’s most-favored-nation drug pricing policy in the GLOBE Model under Medicare Part B.

Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

A recent analysis by Gartner projects low uptake of AI for autonomous supply-chain planning decisions by 2030, but AI does factor into the workflows of the top 25 supply-chain organizations, according to the firm’s annual rankings, but how?

Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five multi-blockbusters by 2030 and expand beyond its obesity and diabetes franchise. Will he and the company be able to deliver?

How truly innovative is the bio/pharma industry? What products, modalities, and companies are behind that innovation? Looking at “first-in-class” new drug approvals, defined as drugs with new mechanisms of action over existing drugs, reveals an interesting picture.

FDA has launched a pilot program to expedite review of investigational new drug (IND) filings with applications for the pilot due by October 30. It is part of the agency’s Operation TrialBlazer initiative, designed to make the US more competitive in early-stage research.

Antibody drug conjugates (ADCs) continue to be a strong growth area, but next-generation drug conjugates, encompassing oligonucleotides, peptides, and other small-molecule payloads, are on the rise.

Sandoz has rolled out a plan to increase its biosimilars portfolio to more than 100 biosimilars, including generic GLP-1’s by 2040, increase manufacturing capacity, and more than double its net sales by 2035.